01—Abstract
Summary
Summary of the 8-K filed October 30, 2025. Cited figures are marked; the original filing is the authoritative source.
Merck & Co. (MRK) reported third-quarter 2025 results with total sales of $17.3 billiona, up 4% nominally and 3% excluding foreign exchange.
Growth was led by KEYTRUDA, which rose 10% to $8.1 billionb (8% ex-FX), and WINREVAIR, which more than doubled to $360 million. GAAP EPS was $2.32 and non-GAAP EPS was $2.58, with both including a $0.10 per-share charge for a milestone payment to LaNova tied to the MK-2010 technology transfer. GAAP net income rose 83% year over year, though that comparison benefits from a 2024 quarter that carried roughly $0.79 per share in aggregate business development charges (EyeBio, MK-1045/Curon, and a Daiichi Sankyo-related item).
Gross margin expanded to 77.7% GAAP and 81.9% non-GAAP. GARDASIL/GARDASIL 9 was the main drag, falling 24% to $1.7 billionc on lower demand in China, and LAGEVRIO declined 64%. Management raised and narrowed its full-year 2025 non-GAAP EPS guidance to $8.93–$8.98 from $8.87–$8.97, and raised the sales outlook to $64.5–$65.0 billion from $64.3–$65.3 billion.
The EPS raise reflects a roughly $0.09d benefit from an amended AstraZeneca Koselugo agreement and operational improvements, partly offset by about $0.04 of dilution from the Verona Pharma acquisition, which closed in October 2025. Management also reiterated a commitment of more than $70 billion to U.S. manufacturing and R&D beginning in 2025, excluding future business development. For investors, the key takeaways are the strong KEYTRUDA franchise (with a subcutaneous KEYTRUDA QLEX now approved across solid tumor indications), the rapid WINREVAIR ramp, and the Verona and Koselugo-related guidance changes.
Offsetting these are the GARDASIL China decline and the ongoing exposure to a patent cliff for KEYTRUDA in the later part of the decade, which the filing does not discuss directly. The updated guidance does not assume additional significant business development transactions, and management plans an investor event at AHA on November 9, 2025.
02—Key points
Key Highlights
- Total Q3 2025 sales of $17.3B, up 4% (3% ex-FX), with KEYTRUDA up 10% to $8.1B and WINREVAIR up 141% to $360M.
- GAAP EPS of $2.32 and non-GAAP EPS of $2.58; both include a $0.10/share LaNova milestone charge for MK-2010 technology transfer.
- Year-over-year EPS growth is inflated by a 2024 base that included ~$0.79/share in aggregate business development charges (EyeBio, MK-1045, Daiichi Sankyo offset).
- GARDASIL/GARDASIL 9 sales fell 24% to $1.7B, driven mainly by lower demand in China; LAGEVRIO fell 64%.
- Full-year 2025 non-GAAP EPS guidance raised and narrowed to $8.93–$8.98 (midpoint up $0.04); sales guidance raised to $64.5–$65.0B.
- Guidance benefits include ~$0.09/share from the amended AstraZeneca Koselugo agreement; Verona Pharma acquisition is a ~$0.04/share negative.
- Gross margin improved to 77.7% GAAP and 81.9% non-GAAP; FDA approved KEYTRUDA QLEX across all solid tumor indications.
03—Questions
Frequently Asked Questions
Why did GAAP EPS rise 87% year over year?
The increase is mainly due to the 2024 quarter, which included a net charge of about $0.79 per share for the EyeBio, Curon (MK-1045) and Daiichi Sankyo transactions. The 2025 quarter also carried a $0.10 per share LaNova milestone charge, so the underlying comparison is more modest than the headline growth rate.
Did Merck raise its 2025 outlook?
Yes, partially. Non-GAAP EPS guidance was raised and narrowed to $8.93–$8.98 from $8.87–$8.97, a midpoint increase of $0.04. Sales guidance was raised to $64.5–$65.0 billion from $64.3–$65.3 billion, narrowing the range. Both figures include foreign exchange headwinds, and the outlook does not assume additional significant business development deals.
What is driving the decline in GARDASIL sales?
Sales fell 24% to $1.7 billion, primarily due to lower demand in China. Excluding China, sales declined 2% (3% ex-FX), reflecting lower demand in Japan after a national catch-up immunization program, partly offset by higher U.S. net pricing and favorable public-sector purchasing.
What were the one-time charges affecting 2025 results and guidance?
Two one-time R&D charges are included in 2025 guidance: a $300 million milestone payment to LaNova for the MK-2010 technology transfer and a $200 million upfront payment to Jiangsu Hengrui Pharmaceuticals for a license agreement. Together they reduce EPS by about $0.16 per share.
04—Continue